These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26638620)

  • 21. The role of PPM1D in cancer and advances in studies of its inhibitors.
    Deng W; Li J; Dorrah K; Jimenez-Tapia D; Arriaga B; Hao Q; Cao W; Gao Z; Vadgama J; Wu Y
    Biomed Pharmacother; 2020 May; 125():109956. PubMed ID: 32006900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meeting Report Europhosphatase 2015: Phosphatases as Drug Targets in Cancer.
    Hoekstra E; Peppelenbosch MP; Fuhler GM
    Cancer Res; 2016 Jan; 76(2):193-6. PubMed ID: 27309387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PINning down the c-Myc oncoprotein.
    Dominguez-Sola D; Dalla-Favera R
    Nat Cell Biol; 2004 Apr; 6(4):288-9. PubMed ID: 15057241
    [No Abstract]   [Full Text] [Related]  

  • 24. Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1.
    Yamaguchi H; Durell SR; Feng H; Bai Y; Anderson CW; Appella E
    Biochemistry; 2006 Nov; 45(44):13193-202. PubMed ID: 17073441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms.
    Wu B; Guo BM; Kang J; Deng XZ; Fan YB; Zhang XP; Ai KX
    Apoptosis; 2016 Mar; 21(3):365-78. PubMed ID: 26714478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.
    Yeh E; Cunningham M; Arnold H; Chasse D; Monteith T; Ivaldi G; Hahn WC; Stukenberg PT; Shenolikar S; Uchida T; Counter CM; Nevins JR; Means AR; Sears R
    Nat Cell Biol; 2004 Apr; 6(4):308-18. PubMed ID: 15048125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
    Hayashi R; Tanoue K; Durell SR; Chatterjee DK; Jenkins LM; Appella DH; Appella E
    Biochemistry; 2011 May; 50(21):4537-49. PubMed ID: 21528848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knockdown of protein phosphatase magnesium-dependent 1 (PPM1D) through lentivirus-mediated RNA silencing inhibits colorectal carcinoma cell proliferation.
    Yin H; Yan Z; Liang Y; Liu B; Su Q
    Technol Cancer Res Treat; 2013 Dec; 12(6):537-43. PubMed ID: 23745790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 30. WIP1 phosphatase at the crossroads of cancer and aging.
    Le Guezennec X; Bulavin DV
    Trends Biochem Sci; 2010 Feb; 35(2):109-14. PubMed ID: 19879149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
    Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
    Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
    Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
    Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
    Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The therapeutic potential of phosphatase inhibitors.
    Vintonyak VV; Antonchick AP; Rauh D; Waldmann H
    Curr Opin Chem Biol; 2009 Jun; 13(3):272-83. PubMed ID: 19410499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
    Akbari MR; Lepage P; Rosen B; McLaughlin J; Risch H; Minden M; Narod SA
    J Natl Cancer Inst; 2014 Jan; 106(1):djt323. PubMed ID: 24262437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphatase assay for multi-phosphorylated substrates using phosphatase specific-motif antibody.
    Chuman Y; Iizuka K; Honda T; Onoue H; Shimohigashi Y; Sakaguchi K
    J Biochem; 2011 Sep; 150(3):319-25. PubMed ID: 21558087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic variants and mutations of PPM1D control the response to DNA damage.
    Dudgeon C; Shreeram S; Tanoue K; Mazur SJ; Sayadi A; Robinson RC; Appella E; Bulavin DV
    Cell Cycle; 2013 Aug; 12(16):2656-64. PubMed ID: 23907125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
    Swisher EM; Harrell MI; Norquist BM; Walsh T; Brady M; Lee M; Hershberg R; Kalli KR; Lankes H; Konnick EQ; Pritchard CC; Monk BJ; Chan JK; Burger R; Kaufmann SH; Birrer MJ
    JAMA Oncol; 2016 Mar; 2(3):370-2. PubMed ID: 26847329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SRC as a target for anti-cancer drugs.
    Levitzki A
    Anticancer Drug Des; 1996 Apr; 11(3):175-82. PubMed ID: 8663905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.